Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
April, 2026
April 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
27282930  
Pablo Corral Shares Key Takeaways on Reducing LDL-Cholesterol to Very Low Levels
Pablo Corral/LinkedIn
Jan 13, 2026, 05:05

Pablo Corral Shares Key Takeaways on Reducing LDL-Cholesterol to Very Low Levels

Pablo Corral, Pharmacology Professor at FASTA University, Past President of Argentine Lipid Society, shared on LinkedIn:

”Reducing LDL-Cholesterol to Very Low Levels: Benefits vs. Risks

Key Takeaways

  1. LDL-C is causal for ASCVD: There is a clear log-linear relationship between absolute LDL-C reduction and cardiovascular risk reduction. Lower is better—no proven lower safety threshold.
  2. Very low LDL-C is physiologically acceptable: Human cells maintain cholesterol homeostasis even at LDL-C levels <25–40 mg/dL; newborns and genetic models support this.
  3. Genetic evidence is reassuring: Lifelong very low LDL-C (e.g., PCSK9 loss-of-function) is associated with lower ASCVD risk and no major safety signals.
  4. No confirmed increase in cancer or neurodegenerative disease with intensive LDL-C lowering; some data even suggest potential benefit.
  5. Diabetes risk is treatment-specific: Statins show a dose-dependent increase in new-onset diabetes; this has notbeen observed with PCSK9 inhibitors, inclisiran, or bempedoic acid.
  6. Hemorrhagic stroke: A small potential risk signal exists, mainly in patients with uncontrolled hypertension—blood pressure control is key.
  7. After ACS, strike early and hard: Achieving LDL-C <30 mg/dL early post-ACS stabilizes and regresses plaque and reduces recurrent events.

Do not de-escalate therapy solely due to very low LDL-C in high-risk patients; the net cardiovascular benefit clearly outweighs potential risks.

10.1007/s40292-025-00708-x ”

Read the full article here.

Article: Reducing LDL-Cholesterol to Very Low Levels: Sailing Between Established Benefits and Potential Risks

Authors: Stefania Angela Di Fusco, Massimo Volpe, Federico Nardi, Andrea Matteucci, Stefano Aquilani, Gaetano Marino, Alessandro Aiello, Furio Colivicchi

Pablo Corral Shares Key Takeaways on Reducing LDL-Cholesterol to Very Low Levels

Stay updated on all scientific advances with Hemostasis Today.

ACS ASCVD Cholesterol Health Hematology Hemostasis Hemostasis News Hemostasis Today LDL Medicine Pablo Corral thrombosis
NewsFeed